Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.44 |
| ▸ | HK1 | P19367 | 2/20 | 0.43 |
| ▸ | HK2 | P52789 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997166 | 0.83 | GAA (0.72) | GAATHRBSMN1; SMN2ALDH1A1LMNA | |
| Bromide SCHEMBL9033663 | 0.82 | GAA (0.71) | GAATHRBSMN1; SMN2ALDH1A1LMNA | |
| Ribose (Furanose) SCHEMBL502577 | 0.80 | ALDH1A1 (0.58) | GAATHRBLGALS9LGALS3LGALS7; LGALS7B | |
| Ribose (Furanose) SCHEMBL19717900 | 0.79 | THRB (0.45) | GAATHRBHK1HK2ALDH1A1 | |
| Ribose (Furanose) SCHEMBL338518 | 0.78 | F7 (0.59) | GAATHRBSMN1; SMN2HK1HK2 | |
| Ribose (Furanose) SCHEMBL14321532 | 0.78 | F7 (0.59) | GAATHRBSMN1; SMN2HK1HK2 | |
| Ribose (Furanose) SCHEMBL18185139 | 0.78 | F7 (0.59) | GAATHRBSMN1; SMN2HK1HK2 | |
| Methyl Nicotinate SCHEMBL2176622 | 0.78 | ALDH1A1 (0.62) | THRBALDH1A1KMT2A | |
| Ribose (Furanose) SCHEMBL23111913 | 0.77 | F7 (0.58) | GAATHRBSMN1; SMN2HK1HK2 | |
| Ribose (Furanose) SCHEMBL15880978 | 0.77 | THRB (0.43) | GAATHRBHK1HK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216412-A1 | OXIDIZED NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) PRECURSOR TREATMENT FOR HEART FAILURE ALLEVIATION INDEPENDENT OF MITOCHONDRIAL PROTEIN DEACETYLATION | UNIVERSITY OF WASHINGTON (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230263817-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | UNIVERSITY OF WASHINGTON (US) | 2023-08-24 | — | — | US | disclosed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2022047182-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | UNIVERSITY OF WASHINGTON (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2021-11-18 | — | — | US | disclosed |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3730507-A1 | NICOTINOYL RIBOSIDE AND NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR USE IN REDUCING TOXICITY INDUCED BY HMG-COA REDUCTASE INHIBITORS | Cornell Research Foundation, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200289535-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| US-10668096-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| EP-1957086-B1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RES FOUNDATION INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20160310517-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| US-9321797-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-9000147-B2 | Nicotyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150072950-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2015-03-12 | — | — | US | disclosed |
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| US-8106184-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1957086-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061798-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | CORNELL RESEARCH FOUNDATION INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, NAMPT, NAPRT | GAA 2009/4885THRB 4542/4885SMN1; SMN2 187/4885 |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | GAA 2173/4885THRB 4263/4885SMN1; SMN2 215/4885 |
| US-20230263817-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | NAMPT, NNT, NQO1 | GAA 3845/4885THRB 3900/4885SMN1; SMN2 1990/4885 |
| US-20160310517-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NADK, NNT, CD38 | GAA 2142/4885THRB 4518/4885SMN1; SMN2 74/4885 |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | GAA 2173/4885THRB 4263/4885SMN1; SMN2 215/4885 |
| US-20200289535-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | GAA 2173/4885THRB 4263/4885SMN1; SMN2 215/4885 |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | GAA 3284/4885THRB 2806/4885SMN1; SMN2 1013/4885 |
| US-10668096-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | GAA 2173/4885THRB 4263/4885SMN1; SMN2 215/4885 |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | GAA 2173/4885THRB 4263/4885SMN1; SMN2 215/4885 |
| US-20150072950-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | GAA 2173/4885THRB 4263/4885SMN1; SMN2 215/4885 |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | GAA 2173/4885THRB 4263/4885SMN1; SMN2 215/4885 |
| US-20240216412-A1 | OXIDIZED NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) PRECURSOR TREATMENT FOR HEART FAILURE ALLEVIATION INDEPENDENT OF MITOCHONDRIAL PROTEIN DEACETYLATION | NAMPT, SIRT3, NDUFAB1 | GAA 2708/4885THRB 2220/4885SMN1; SMN2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.